Vivos Therapeutics, Inc. (VVOS)

Market Cap	21.57M
Revenue (ttm)	14.58M
Net Income (ttm)	-12.57M
Shares Out	4.84M
EPS (ttm)	-3.52
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	259,152
Open	4.520
Previous Close	4.650
Day's Range	4.180 - 4.520
52-Week Range	1.910 - 12.750
Beta	7.64
Analysts	Strong Buy
Price Target	6.30 (+41.26%)
Earnings Date	Nov 14, 2024

About VVOS

Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and s...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Dec 11, 2020
• Employees: 123
• Stock Exchange: NASDAQ
• Ticker Symbol: VVOS
• Website: https://www.vivos.com

Financial Performance

In 2023, Vivos Therapeutics's revenue was $13.80 million, a decrease of -13.87% compared to the previous year's $16.02 million. Losses were -$13.58 million, -43.04% less than in 2022.

Analyst Forecast

According to 2 analysts, the average rating for VVOS stock is "Strong Buy." The 12-month stock price forecast is $6.3, which is an increase of 41.26% from the latest price.

Price Target

$6.3

(41.26% upside)

Analyst Consensus: Strong Buy